Stellar Biotechnologies and Neovacs S.A. have entered a joint venture agreement to manufacture and sell conjugated therapeutic vaccines using Stellar’s Keyhole Limpet Hemocyanin (KLH). The purpose of the joint venture is to produce Neovacs’ Kinoid immunotherapy product candidates, including IFNa-Kinoid, as well as potentially manufacture and sell other KLH-based immunotherapy vaccine products to third party customers worldwide. Neovacs is involved in the development of active i...